Sai Life Sciences   Report issue

For profit Phase 1 Phase 4
Founded: Hyderabad India (1999)

Organization Overview

First Clinical Trial
2010
NCT01373567
First Marketed Drug
2019
dapsone (aczone)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

SAI LIFE SCIENCES | Sai Skin Care Clinic, H.No.:2-1-409, Nallakunta, O.U.Road, Hyderabad

Active Ingredients

Marketed Drugs (1)

dapsone (aczone) (2019)

Drugs in Phase 4 Trials (1)

mechlorethamine (mustargen) (1 trial)

Drugs in Phase 1 Trials (3)

buparlisib (1 trial)

carboplatin (paraplatin) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Psoriasis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 4